Live Breaking News & Updates on Meenakshi Nevatia

Stay updated with breaking news from Meenakshi nevatia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Shri Ram Economics Summit 2024: A Confluence of Ideas and Innovation

Shri Ram Economics Summit 2024: A Confluence of Ideas and Innovation
indianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianexpress.com Daily Mail and Mail on Sunday newspapers.

India , Shelly-malhotra , Kamaksha-saraf , Samsung , Economics-society , Summer-fields-school , Meenakshi-nevatia , Managing-director , Pfizer-india , Gautam-chikermane , Vice-president , Pronab-sen

Funding key to pharma target of $130bn: CEOs | Hyderabad News

Innovation, talent, government support, and funding are crucial for Indian pharma to achieve its target of $130 billion by 2030 and $500 billion by 2047. Learn more about the insights from top CEOs in the industry. ....

Hyderabad , Andhra-pradesh , India , China , Meenakshi-nevatia , Satyanarayana-chava , Piramal-pharma , Satish-reddy , Nandini-piramal , Stefan-stoffel , Pfizer , Hyderabad-news

Glenmark partners with Pfizer to launch oral drug for atopic dermatitis in India

Glenmark partners with Pfizer to launch oral drug for atopic dermatitis in India
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

India , China , Japan , Meenakshi-nevatia , Alok-malik , Central-drugs-standard-control-organization , Glenmark-pharmaceuticals-ltd , Drug-administration , Pfizer , European-medicines-agency , Glenmark-pharmaceuticals , Country-president

Glenmark partners with Pfizer to launch abrocitinib in India to treat atopic dermatitis

Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies. ....

India , Japan , China , Alok-malik , Meenakshi-nevatia , European-medicines-agency , Pfizer , Central-drugs-standard-control-organization , India-formulations , Abrocitinib , Atopic-dermatitis , Glenmark